PBYI vs. RAPT, AKBA, MRNS, URGN, LBPH, PAHC, LYEL, AVBP, SAGE, and ANAB
Should you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include RAPT Therapeutics (RAPT), Akebia Therapeutics (AKBA), Marinus Pharmaceuticals (MRNS), UroGen Pharma (URGN), Longboard Pharmaceuticals (LBPH), Phibro Animal Health (PAHC), Lyell Immunopharma (LYEL), ArriVent BioPharma (AVBP), Sage Therapeutics (SAGE), and AnaptysBio (ANAB). These companies are all part of the "pharmaceutical preparations" industry.
RAPT Therapeutics (NASDAQ:RAPT) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, community ranking, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.
Puma Biotechnology received 449 more outperform votes than RAPT Therapeutics when rated by MarketBeat users. Likewise, 66.54% of users gave Puma Biotechnology an outperform vote while only 66.17% of users gave RAPT Therapeutics an outperform vote.
RAPT Therapeutics currently has a consensus target price of $24.67, suggesting a potential upside of 515.13%. Puma Biotechnology has a consensus target price of $7.00, suggesting a potential upside of 81.82%. Given Puma Biotechnology's higher possible upside, analysts plainly believe RAPT Therapeutics is more favorable than Puma Biotechnology.
99.1% of RAPT Therapeutics shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 6.6% of RAPT Therapeutics shares are held by insiders. Comparatively, 23.7% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Puma Biotechnology had 2 more articles in the media than RAPT Therapeutics. MarketBeat recorded 3 mentions for Puma Biotechnology and 1 mentions for RAPT Therapeutics. RAPT Therapeutics' average media sentiment score of 0.97 beat Puma Biotechnology's score of 0.43 indicating that Puma Biotechnology is being referred to more favorably in the news media.
Puma Biotechnology has a net margin of 6.79% compared to Puma Biotechnology's net margin of 0.00%. RAPT Therapeutics' return on equity of 35.49% beat Puma Biotechnology's return on equity.
RAPT Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500.
Puma Biotechnology has higher revenue and earnings than RAPT Therapeutics. RAPT Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.
Summary
Puma Biotechnology beats RAPT Therapeutics on 14 of the 18 factors compared between the two stocks.
Get Puma Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Puma Biotechnology Competitors List
Related Companies and Tools
